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I read with interest the review by Prof. Gutierrez and
colleagues on hemorrhagic shock [1]. The treatment of
hemorrhagic shock is addressed in the review, and mention is
made of the main goals: to stop the source of hemorrhage
and to restore the circulating volume. Conserving blood
products, on the grounds of cost, restricted availability and
their pathophysiological effects, is becoming a necessary shift
in the approach to these difficult patients and was not
touched upon in the review. There have been clear advances
in recent years in developing other strategies to aggressively
stem the flow.
Damage control surgery in trauma and embolization are
certainly useful tools in the control of bleeding.
Pharmacological manipulation of the coagulation system is a
rapidly expanding field of research. Activated recombinant
factor VII (Factor VIIa) is a hemostatic agent originally
developed for the hemophilia population, but it is emerging as
a very effective way of treating uncontrolled hemorrhage in
patients without pre-existing factor deficiencies. A hetero-
geneous case series of major hemorrhage was reported last
year, in which 80% of the cases given Factor VIIa responded
with complete or partial cessation of bleeding [2]. Data from
the trauma environment with massive bleeding suggest a
useful role for Factor VIIa [3], and further studies are ongoing.
Competing interests
The author declares that he has no competing interests.
Letter
Hemorrhagic shock: a review
Martin Chapman
Assistant Professor, University of Toronto and Staff Intensivist, Sunnybrook and Women’s College Health Sciences Centre, Toronto, Canada
Corresponding author: Martin Chapman, dr.martin.chapman@sw.ca
Published online: 30 June 2004 Critical Care 2004, 8:396 (DOI 10.1186/cc2898)
This article is online at http://ccforum.com/content/8/5/396
© 2004 BioMed Central Ltd See Review, page 373
Authors’ response
H David Reines, Marian Wulf-Gutierrrez and Guillermo Gutierrez
We thank Dr Chapman for his comments on new approaches
to control hemorrhage. We agree that conservation of blood
and blood products is not just an economic concern, but it is
necessary to protect a limited resource and to prevent
untoward effects of such products. Our sections on
hypertonic saline and the use of blood substitutes were
meant to address this issue directly. We limited our
discussion to a general discussion of hemorrhagic shock and
did not specifically address surgical approaches to the
control of bleeding. ‘Damage control’ and packing is a valid
concept in the treatment of severely injured patients with
hemorrhage [4]. This approach was frequently used in
battlefields, and has become more popular in civilian injury as
a method for preventing death from coagulopathy and
hypothermia in the operating room. The use of radiological
embolization as a technique to control ongoing hemorrhage
from solid organs such as the spleen and the liver has also
supplemented its use in pelvic hemorrhage. This technique is
not necessarily an ideal therapy for patients who are in shock.
Operative intervention is still necessary in unstable patients.
We agree that pharmacological manipulation may be an
adjunct to good surgical practice. There are anecdotal
reports on the use of activated recombinant factor VII to
control bleeding in trauma patients, as well as in numerous
other patient populations who do not have hemophilia. The
unencumbered use of this extremely expensive treatment has
led to the loss of millions of dollars in uncompensated care
and occasional significant complications. The present status
of this potentially important addition to the armamentarium is
under investigation. Prospective studies need to be
performed to establish efficacy and criteria for use before we
embark on this new approach.
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